Nov 06, 2018
FDA approves Zulresso of Sage Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, receives U.S. approval for its postpartum depression (PPD) drug Zulresso from the Food and Drug Administration when received 17-1 in favour of the therapy...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper